Just another reason to query the Daybue revenue downgrade:
Joel Beatty | Robert W. Baird Stock Analyst - TipRanks.comJoel Beatty is a 4.69-star Wall Street Analyst at Robert W. Baird. Joel Beatty's focuses on the Healthcare sector and covers 72 stocks with a 48.99% success rate
Joel Beatty has given his Buy rating due to a combination of factors surrounding ACADIA Pharmaceuticals’ financial performance and market opportunities. Despite a decrease in revenue guidance for Daybue, Beatty acknowledges the potential for this drug to be a longer-term growth opportunity. He cites the steady increase in Daybue’s revenue over the previous quarters and the management’s report that over 30% of diagnosed Rett syndrome patients in the United States had started treatment by the end of the second quarter. Additionally, the rate of discontinuations decreased, and patient growth continued, suggesting a positive trend for future sales.
Kens
Share Price, page-11133
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.90 |
Change
-0.330(2.03%) |
Mkt cap ! $2.034B | |||
| Open | High | Low | Value | Volume |
| $16.33 | $16.37 | $15.78 | $9.238M | 578.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7838 | $17.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.31 | 412 | 1 |
View Market Depth
| Last trade - 15.59pm 13/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |